News

SEATTLE, Wash. and VANCOUVER, British Columbia, February 24, 2021 – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that three posters featuring data on smoker and e-cigarette user behavior will be presented today, Wednesday, February 24th at the SRNT…

Designed to Assess the Efficacy and Safety of 3 mg Cytisinicline Three Times Daily Dosing Compared to Placebo. Phase 3 ORCA-2 Trial to Enroll 750 Smokers Across 15 Clinical Trial Sites in the United States. SEATTLE, Wash and VANCOUVER, British Columbia, October 7, 2020 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company…

Subjects in the Cytisinicline Arm Were 55% More Likely to Quit Smoking at 6 Months Compared to Subjects Who Received Varenicline. Significantly Fewer Overall Adverse Events Were Reported in Cytisinicline-Treated Subjects (p<0.001) Cytisinicline U.S. Phase 3 Trial Expected to Begin in Fourth Quarter 2020. SEATTLE, Wash and VANCOUVER, British Columbia, September 18, 2020 — Achieve…

Provides Mechanistic Rationale for the Clinical Findings that Cytisinicline (Cytisine) Treatment is Associated with Lower Rates of Nausea and Vomiting compared to Chantix. SEATTLE, Wash and VANCOUVER, British Columbia, September 18, 2020 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation,…

SEATTLE, Wash and VANCOUVER, British Columbia, September 10, 2020 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that cytisinicline data will be featured in two presentations on Friday, September 18th, at the SRNT-E virtual conference.  Both presentations evaluate…